Compare BAND & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | PHAR |
|---|---|---|
| Founded | 2000 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.9M | 917.4M |
| IPO Year | 2017 | 2020 |
| Metric | BAND | PHAR |
|---|---|---|
| Price | $68.55 | $12.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $24.50 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 1.2M | 13.8K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $204,113,000.00 | N/A |
| Revenue This Year | $15.16 | $10.04 |
| Revenue Next Year | $6.18 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $12.50 | $9.54 |
| 52 Week High | $71.76 | $21.34 |
| Indicator | BAND | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 77.48 | 35.59 |
| Support Level | $14.27 | $11.84 |
| Resistance Level | N/A | $13.44 |
| Average True Range (ATR) | 4.61 | 0.42 |
| MACD | 0.38 | 0.09 |
| Stochastic Oscillator | 82.85 | 33.16 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of its revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.